Brexit will threaten UK pharmaceutical research and investment, select committee warns
An evidence session on Tuesday will examine how different scenarios relating to future customs and trading arrangements between the EU and the UK might affect the industry
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MPs have raised serious concerns about the post-Brexit regulation of the pharmaceuticals sector, warning that the UK’s departure from the EU could make Britain a less desirable place for investment and development.
Ahead of a public evidence session on Tuesday, the Business, Energy and Industrial Strategy Committee on Monday published written evidence of its inquiry into the pharmaceutical industry launched back in September.
Based on submissions from 19 organisations, including the Association of British Healthcare Industries, the British Generic Manufacturers Association, the British Medical Association and several publicly listed companies, the report concludes that the possible threat of Brexit to research and development is notable.
“There are serious concerns raised around the future regulation of pharmaceuticals, mutual recognition of medicines, and the prospect of damaging disruption to cross-EU drug supply chains,” said Rachel Reeves, chair of the committee.
“This is very concerning, with uncertainty risking the UK becoming a less desirable place for investment and development in a growing, productive industry,” she added.
An evidence session on Tuesday will examine how different scenarios relating to future customs and trading arrangements between the EU and the UK might affect the industry, and what the Government should be seeking to achieve in negotiations, the committee said.
The latest report follows a string of similar warnings on what implications Brexit might have for the healthcare sector.
In September, researchers writing in The Lancet medical journal said that Brexit could have a “potentially catastrophic” impact on the NHS.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments